News and Announcements
Kazia (ASX: KZA) commences fifth trial of GDC-0084 with leading US cancer centre
- Published August 15, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights
- Kazia Therapeutics has announced that Memorial Sloan Kettering Cancer Center in New York will investigate the potential use of GDC-0084 for cancer that has spread to the brain.
- The new trial will investigate whether GDC-0084 has the potential to enhance the effects of radiotherapy as treatment for patients with solid tumour brain metastases.
- The trial will involve 18-30 patients over a period of two years bringing the total number of ongoing trials with GDC-0084 to five.
Australian biotechnology company Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), has announced that Memorial Sloan Kettering Cancer Center (MSK) in New York will investigate the potential use of Kazia’s investigational new drug, GDC-0084. The drug will be investigated in combination with radiotherapy in phase I clinical trial for cancer that has spread to the brain.
Research shows up to 30% of patients with metastatic cancer will develop secondary tumours in the brain. Despite the best care utilising radiotherapy as treatment, 30-50% of patients will progress within a year.
The new trial will investigate whether GDC-0084 has the potential to enhance the effects of radiotherapy as treatment for patients with solid tumour brain metastases along with leptomeningeal metastases. It is testing the hypothesis that GDC-0084 will assist in radiotherapy resistance. In recent animal models of some brain cancers, activation of the PI3K pathway has contributed to radiotherapy resistance. Implementation of GDC-0084 is used as a PI3K inhibitor that crosses the blood-brain barrier in an attempt to reduce radiotherapy resistance.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
